Subscription Information
http://ajcc.aacnjournals.org/subscriptions/
Information for authors
http://ajcc.aacnjournals.org/misc/ifora.xhtml
Submit a manuscript
http://www.editorialmanager.com/ajcc
Email alerts
http://ajcc.aacnjournals.org/subscriptions/etoc.xhtml
AJCC, the American Journal of Critical Care, is the official peer-reviewed research
journal of the American Association of Critical-Care Nurses (AACN), published
bimonthly by The InnoVision Group, 101 Columbia, Aliso Viejo, CA 92656.
Telephone: (800) 899-1712, (949) 362-2050, ext. 532. Fax: (949) 362-2049.
Copyright 2012 by AACN. All rights reserved.
ERIPARTUM
CARDIOMYOPATHY:
REVIEW AND PRACTICE
GUIDELINES
By Leah Johnson-Coyle, RN, MN, Louise Jensen, RN, PhD, and Alan Sobey, MD
www.ajcconline.org
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
89
Epidemiology
The reported incidence of PPCM varies because
the diagnosis is not always consistent and a comparison with age-matched nonpregnant women does
not exist.4,6,7 Reported incidences range from 1 in
299 live births in Haiti8 to 1 in 2229 live births in
Southern California9 to 1 in 4000 live births in the
United States.4 The wide variation most likely is the
result of geographic differences and
reporting patterns.10 Also, limited access
to echocardiography in some areas
may lead to overestimation of PPCM.11
Several risk factors predispose a
woman to PPCM, including increased
maternal age, multiparity, multiple
pregnancies, and pregnancies complicated by preeclampsia and gestational
hypertension.4,6,12 Although PPCM
occurs more frequently in women at
the upper and lower extremes of child-bearing ages
and in older women of higher parity,4,13 the disease
has also been reported in 24% to 37% of young
primigravid women.3,6,14 In contrast, the results of a
large population-based study from Haiti suggested
that multiparity and increasing maternal age are not
risk factors.8 Demakis et al12 and Brar et al15 found
Initial severity
of left ventricular
dysfunction is
not necessarily
predictive of
long-term outcome.
90
Etiology
PPCM is distinguished from other forms of
cardiomyopathies by its occurrence during pregnancy.16 Precise mechanisms that lead to PPCM
remain poorly defined. Many etiological processes
have been suggested: viral myocarditis, abnormal
immune response to pregnancy, maladaptive response
to hemodynamic stresses of pregnancy, stress-activated
cytokines, excessive prolactin excretion, and prolonged tocolysis.4,10,17,18 Also, a familial predisposition
to PPCM has been reported.19-21 Although underlying genetic variants common to dilated cardiomyopathies are being proposed,22 a genetic basis specific
to PPCM has not been systematically studied.23 The
European Society of Cardiology currently classifies
PPCM as a nonfamilial, nongenetic form of dilated
cardiomyopathy.24
Viral Myocarditis
Viral myocarditis has been proposed as the main
mechanism for PPCM and was first reported by
Goulet et al.25 This proposal was later supported by
Melvin et al,26 who found myocarditis during endomyocardial biopsy in 3 women with PPCM. The biopsy
specimens had dense lymphocytic infiltration with
a variable amount of myocytic edema, necrosis, and
fibrosis. Others27 have also reported an association
between PPCM and viral myocarditis. In a study by
Felker et al,28 62% of women with PPCM had
myocarditis or borderline myocarditis on biopsy;
however, clinical outcomes did not differ between
women with and without myocarditis.
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
www.ajcconline.org
www.ajcconline.org
erythropoietin, and hence hematocrit levels.18 Hilfiker-Kleiner et al31 discovered that PPCM develops
in mice bred to have a cardiomyocyte-specific deletion of STAT3, a protein that plays a key role in
many cellular processes such as cell growth and
apoptosis. The deletion of STAT3 led to enhanced
expression of cardiac cathepsin D, promoting the
formation of a 16-kD form of prolactin. In women
with PPCM, STAT3 protein levels were low in the
heart, and serum levels of activated cathepsin D
and 16-kD prolactin were elevated.16,31
Selenium and Malnutrition
Nutritional disorders, such as deficiencies in
selenium and other micronutrients, were thought
to play a role in the pathogenesis of PPCM.12,26 Deficiencies of selenium increase cardiovascular susceptibility to viral infections, hypertension, and
hypocalcemia. However, Fett et al32 concluded that
neither low serum levels of selenium nor deficiencies of other micronutrients (vitamins A, B12, C, E,
and b-carotene), played a significant role in the
development of PPCM in Haitian women. In contrast, women with PPCM from the
Sahelian region of Africa had low
levels of selenium.33
Viral myocarditis
has been
proposed as the
main mechanism
for peripartum
cardiomyopathy.
Prolonged Tocolysis
Prolonged tocolysis refers to
the use of tocolytic agents (b-sympathomimetic drugs) for more
than 4 weeks.18 The association
between tocolytic therapies and
heart failure appears to be unique
to pregnancy. Tocolytic agents are used for the management of various other conditions without the
occurrence of signs and symptoms of heart failure
like those experienced by pregnant women. Such
signs and symptoms may develop in pregnant
women as a result of normal physiological changes
that occur, including an increase in circulating
blood volume.18 Lampert et al34 found an association between use of tocolytic therapies and development of pulmonary edema in pregnant women and
proposed a link between chronic use of b-sympathomimetic medications and PPCM.
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
91
Magnetic
resonance images
can be used to
measure global
and segmental
contraction and
identify inflammatory processes.
92
Management
Compensated Heart Failure
Management of PPCM is similar to standard
treatment for other forms of heart failure.4,39,41 However, no randomized clinical trials have been done
to evaluate these therapies specifically in PPCM.
Furthermore, careful attention should be paid to fetal
safety and to excretion of drug or drug metabolites
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
www.ajcconline.org
www.ajcconline.org
Cough
Heart palpitations/tachycardia
Sudden weight gain, fluid retention
Arrhythmias
Paroxysmal nocturnal dyspnea
Hepatomegaly
Weakness
Diagnostic testing
Complete family history, to identify possible familial association
Serum tests
Complete blood cell count with differential
Creatinine and urea levels
Electrolyte levels, including magnesium and calcium
Levels of cardiac enzymes, including troponin
Level of B-type natriuretic peptide and/or N-terminal
pro-B-type natriuretic protein
Liver function and level of thyroid-stimulating hormone
Chest radiograph
Electrocardiogram
Transthoracic echocardiogram
Cardiac magnetic resonance imaging and/or endomyocardial
biopsy (when indicated)
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
93
often required; however, attempts involving noninvasive ventilation may obviate intubation.44 Noninvasive ventilation must be used with caution because
of the high risk for aspiration. Breathing is supported
with supplemental oxygen to relieve signs and symptoms related to hypoxemia and is assessed via continuous pulse oxymetry. Women should have cardiac
monitoring, including ST-segment monitoring when
available.13,35 Blood pressure should be monitored
with noninvasive blood pressure cuffs until arterial
catheters are placed. Venous and arterial access
should be obtained early so that medications can
be administered promptly and monitoring can be
streamlined.35 Some clinicians39 advocate for the use
of pulmonary artery catheters in women whose heart
failure is refractory; however, this logic has been
questioned because many of the drugs used to treat
PPCM produce benefits by mechanisms that cannot
be assessed by measurement of short-term changes
in hemodynamic status. Pulmonary artery catheters
may be beneficial in patients with heart failure, but
little information is available on their use in
women with PPCM.
94
In antepartum women, fetal heart rate monitoring should be started early because abnormalities in
fetal heart rate tracings are common when maternal
oxygenation and circulation are compromised.35 Medical stabilization of the mothers condition is critical
and may result in resolution of fetal distress and prevent the need for emergency cesarean delivery that
most likely would be poorly tolerated by the mother.35
Women with acute heart failure benefit from
intravenous administration of positive inotropic
agents such as dobutamine and milrinone, none of
which are contraindicated in pregnancy.44 Positive
inotropic agents improve cardiac performance, facilitate diuresis, preserve end-organ function, and promote clinical stability.13,17,39 Dobutamine requires
b-receptors for its inotropic effects, whereas milrinone
does not, an important distinction in planning care
for a patient who is being treated with b-blocking
drugs.39 Furthermore, milrinone has vasodilating
properties for both the systemic and the pulmonary
circulation, a mechanism that may be a marked
benefit over other inotropic agents. In women with
systolic blood pressure less than 90 mm Hg, dobutamine may be preferred over milrinone.44 Vasodilatory
drugs such as nitroglycerin and nitroprusside also
may be of benefit.35,39 Nitroprusside should be used
with caution in pregnant women because the toxic
effects of thiocyanate can be harmful to the fetus.20,42
Clinicians should not focus therapy on a specific blood pressure value that might or might not
indicate hypotension; rather, they should focus on
signs and symptoms associated with poor cardiac
output and hypoperfusion, such as cold clammy
skin, cool upper and lower extremities, decreased
urine output, and altered mental status.39 Inotropic
agents are of greatest value in women who have
relative hypotension and an intolerance or no
response to vasodilators and diuretics.42 Regardless,
if invasive monitoring of hemodynamic status is
used, once the clinical status of the woman has
stabilized, every effort should be made to devise an
oral regimen that can maintain symptomatic improvement and reduce the subsequent risk of any deterioration in her condition.42
Left ventricular thrombus is common in women
with PPCM whose ejection fraction is less than
35%.2,38 Warfarin should be given to postpartum
women whose ejection fraction is 35% or less, and
heparin or a low-molecular-weight heparin should
be given to women who are pregnant and have a
similar ejection fraction.20,35 Anticoagulation therapy
should be continued until left ventricular function
is normal according to echocardiographic findings.13,39 Arrhythmias should be aggressively treated
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
www.ajcconline.org
www.ajcconline.org
Nonpharmaceutical therapies
Low-sodium diet: limit of 2 g sodium per day
Fluid restriction: 2 L/day
Light daily activity: if tolerated (eg, walking)
Oral pharmaceutical therapies
Antepartum management of peripartum cardiomyopathy
b-blocker
Carvedilol (starting dose 3.125 mg twice a day, target dose
25 mg twice a day)
Extended-release metoprol (starting dose 0.125 mg daily, target
dose 0.25 mg daily)
Vasodilator
Hydralazine (starting dose 10 mg 3 times a day, target dose 40 mg
3 times a day)
Digoxin (starting dose 0.125 mg daily, target dose 0.25 mg daily)
Monitor serum levels
Thiazide diuretic (with caution)
Hydrochlorothiazide (12.5-50 mg daily)
May also consider loop diuretic with caution
Low-molecular-weight heparin if ejection fraction <35%
Postpartum management of peripartum cardiomyopathy
Angiotensin-converting enzyme (ACE) inhibitor
Captopril (starting dose 6.25-12.5 mg 3 times a day,
target dose 25-50 mg 3 times a day)
Enalapril (starting dose 1.25-2.5 mg 2 times a day,
target dose 10 mg 2 times a day)
Ramipril (starting dose 1.25-2.5 mg 2 times a day,
target dose 5 mg 2 times a day)
Lisinopril (starting dose 2.5-5 mg daily, target dose
25-40 mg daily)
Angiotensin-receptor blocker (if ACE inhibitor not tolerated)
Candesartan (starting dose 2 mg daily, target dose 32 mg daily)
Valsartan (starting dose 40 mg twice a day, target dose 160 mg
twice a day)
Consider nitrates or hydralazine if woman is intolerant to ACE
inhibitor and angiotensin-receptor blocker
Loop diuretic
Furosemide intravenously or by mouthdosing considerations
should be made on the basis of creatinine clearance
Glomerular filtration rate >60 mL/min per 1.73 m2:
furosemide 20-40 mg every12-24 h
Glomerular filtration rate <60 mL/min per 1.73 m2:
furosemide 20-80 mg every 12-24 h
Vasodilator
Hydralazine (starting dose 37.5 mg 3 or 4 times a day, target dose
40 mg 3 times a day)
Isorbide dinitrate (starting dose 20 mg 3 times a day, target dose
40 mg 3 times a day)
Aldosterone antagonist
Spironolactone (starting dose 12.5 mg daily, target dose
25-50 mg daily)
Eplerenone (starting dose 12.5 mg daily, target dose 25-50 mg daily)
b-blocker as above
Warfarin if ejection fraction <35%
aBased
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
95
If no improvement clinically:
Consider cardiac magnetic resonance imaging
Perform endomyocardial biopsy to detect viral myocarditis
(if not previously completed)
Assist devices:
Intra-aortic balloon pump
Left ventricular assist devices
Extracorporeal membrane oxygenation
Transplantation
If a woman remains refractory to therapy, consult your institutions
guidelines for bromocriptine or cabergoline administration for
suppression of prolactin production
aBased
96
Outcomes of PPCM
Prognosis of PPCM is positively related to the
recovery of ventricular function.17 Failure of heart
size to return to normal is associated with increased
mortality and morbidity.4 Women with persistent
left ventricular dysfunction are less likely to survive
and recover normal cardiac function than are women
with improved left ventricular function. A fractional
shortening less than 20% and a left ventricular
diastolic dimension of 6 cm or greater at the time
of diagnosis are associated with a more than 3-fold
higher risk for persistent cardiac dysfunction.53
Sliwa et al3 found that ejection fraction was the
strongest predictor of outcome in women with PPCM.
Abboud et al17 reported that 50% of women with
PPCM recover baseline ventricular function within
6 months of delivery. In contrast, Ntusi and Mayosi18
found that only 30% of women with PPCM have
complete recovery of cardiac function; most have
partial recovery. Medical therapy as outlined in the
ACCF/AHA guidelines39 should be continued when
a woman does not recover function. When appropriate, implantation of defibrillators to prevent sudden
cardiac death and use of cardiac revascularization
therapy should be considered.
Reported mortality rates for PPCM vary widely.
In a study by Sliwa et al,3 the mortality rate in 29
women was 32%, whereas in a large populationbased study in Haiti by Fett et al,8 the mortality rate
was 15.8%. In a study of 123 women by Elkayam
et al,5 the rate was 9% at a mean follow-up time of
24 months. Brar et al15 concluded that mortality
rates associated with PPCM were lower than initially
reported at 2.5%, and Mielniczuk et al9 reported a
mortality rate of 1.36% to 2.05%. Earlier diagnosis,
coupled with modern management of heart failure,
most likely has an important influence on the mortality associated with PPCM.9,15 Although rates have
improved, mortality remains extremely high in
women with PPCM.
One of the most frequently cited issues for
women who survive PPCM is whether or not they
can safely become pregnant again.5,14 No clearly
established recommendations for future pregnancies
in these women exist.20 Left ventricular recovery and
function are considered the most reliable prognostic
factors and predictors of survival in subsequent
pregnancies.20 Future pregnancies are not recommended in women with persistent heart failure,
because the heart most likely would not be able to
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
www.ajcconline.org
tolerate the increased cardiovascular workload associated with the pregnancy.5,13 Women whose cardiomyopathy appears to have resolved are a more
difficult group to counsel.4 Because multiparity has
been associated with PPCM, subsequent pregnancies can increase the risk for recurrent episodes of
PPCM, irreversible cardiac damage and decreased
left ventricular function, worsening of a womans
clinical condition, and even death.4,14
Williams et al35 have suggested that dividing
women into 2 categories (recovered vs nonrecovered
left ventricular function) is most appropriate for
counseling on future pregnancy. Even though the
cardiac function has normalized in the group of
women with recovered cardiac function, the left
ventricular contractile reserve may remain impaired,
and recurrence of PPCM is still possible.4,5 The subset of women with persistent left ventricular systolic
dysfunction should be counseled against subsequent pregnancies; the risks are 19% higher for
maternal death than among women with PPCM
whose heart failure has resolved.35
Conclusion
PPCM affects previously healthy women in the
final month of pregnancy and up to 5 months after
delivery.4 The diagnosis is based on 4 criteria.1,4 For
some women, the clinical and echocardiographic
status improve rapidly and sometimes return to
normal. In other women, the clinical condition rapidly worsens, no improvement occurs with medical
therapy, and chronic heart failure from persistent
ventricular dysfunction develops.5 No single explanation of the pathogenesis of PPCM is relevant for
all women; the disease has a multifactorial origin.
In acute care, treatment may involve the use of
intravenous vasodilators, inotropic medications, an
intra-aortic balloon pump, ventricular assist devices,
and/or extracorporeal membrane oxygenation.20,50
Survivors of PPCM often recover from left ventricular dysfunction; however, they may be at risk for
recurrence of heart failure and death in subsequent
pregnancies. Women with chronic left ventricular
dysfunction should be managed according to
ACCF/AHA guidelines.39 Careful assessment of risk
factors in pregnant women could help in the prevention of PPCM. Tools to stratify women by risk who
have recovered from PPCM are needed to predict
the risk of future pregnancies.
eLetters
Now that youve read the article, create or contribute to an
online discussion on this topic. Visit www.ajcconline.org
and click Submit a response in either the full-text or
PDF view of the article.
www.ajcconline.org
FINANCIAL DISCLOSURES
None reported.
REFERENCES
1. Hibbard JU, Lindheimer M, Lang RM. A modified definition
for peripartum cardiomyopathy and prognosis based on
echocardiography. Obstet Gynecol. 1999;4(2):311-315.
2. Tidswell M. Peripartum cardiomyopathy. Crit Care Clin.
2004;20:777-788.
3. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A,
Sareli P. Peripartum cardiomyopathy: analysis of clinical
outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35(3):701-705.
4. Pearson G, Veille J, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute
and Office of Rare Diseases (National Institutes of Health)
workshop recommendations and review. JAMA. 2000;283(9):
1183-1188.
5. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum
cardiomyopathy. N Engl J Med. 2001;344(21):1567-1571.
6. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy.
Lancet. 2006;368(9536):687-693.
7. James P. A review of peripartum cardiomyopathy. Int J Clin
Pract. 2004;58(4):363-365.
8. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year
prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin
Proc. 2005;80(12):1602-1606.
9 Mielniczuk LM, Williams K, Davis DR, et al. Frequency of
peripartum cardiomyopathy. Am J Cardiol. 2006;97(12):
1765-1768.
10. Ro A, Frishman W. Peripartum cardiomyopathy. Cardiol
Rev. 2006:14(1):35-42.
11. Sliwa K, Tibazarwa K, Hilfiker-Kleiner D. Management of
peripartum cardiomyopathy. Curr Heart Fail Rep. 2008;5(5):
238-244.
12. Demakis JG, Rahimtoola S, Sutton GC, et al. Natural course
of peripartum cardiomyopathy. Circulation. 1971;44(6):
1053-1061.
13. Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: causes,
diagnosis, and treatment. Cleve Clin J Med. 2009;76(5):
289-296.
14. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated
cardiomyopathy: clinical characteristics and a comparison
between early and late presentation. Circulation. 2005;111
(16):2050-2055.
15. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality,
and racial differences in peripartum cardiomyopathy. Am
J Cardiol. 2007;100(2):302-304.
16. Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18(5):173-179.
17. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L,
Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118(3):295-303.
18. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol.
2009;131(2):168-179.
19. Pearl W. Familial occurrence of peripartum cardiomyopathy.
Am Heart J. 1995;129(2):421-422.
20. Moioli M, Menada MV, Bentivoglio G, Ferrero S. Peripartum
cardiomyopathy. Arch Gynecol Obstet. 2010;281(2):183-188.
doi:10.1007/s00404-009-1170-5.
21. Baruteau AE, Leurent G, Martins R, et al. Peripartum cardiomyopathy in the era of cardiac magnetic resonance
imaging: first results and perspectives. Int J Cardiol. 2010;
144(1):143-145.
22. van Spaendonck-Zwarts KY, van Tintelen P, van Veldhuisen
DJ, et al. Peripartum cardiomyopathy as a part of familial
dilated cardiomyopathy. Circulation. 2010;121:2169-2175.
23. Burkett EL, Hershberger RE. Clinical and genetic issues in
familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;
45(7):969-981.
24. Elliott P, Andersson B, Arbustini E, et al. Classification of
the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial
and Pericardial Disease. Eur Heart J. 2008;29(2):270-276.
25. Goulet B, McMillan T, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puer-
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
97
98
40. Ntusi NB, Chin A. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol.
2009;19(6):1324-1325.
41. Carlin AJ, Alfirevic Z, Gyte ML. Interventions for treating
peripartum cardiomyopathy to improve outcomes for
women and babies. Cochrane Database Syst Rev. 2010(9):
CD008589. doi:10.1002/14651858.CD008589.pub2.
42. Heart Failure Society of America. Executive summary:
HFSA 2006 comprehensive heart failure practice guideline.
J Card Fail. 2006;12(1):10-38.
43. Egan DJ, Bisanzo MC, Hutson HR. Emergency department
evaluation and management of peripartum cardiomyopathy.
J Emerg Med. 2009;36(2):141-147.
44. Arnold JM, Liu P, Demers C, et al; Canadian Cardiovascular
Society. Canadian Cardiovascular Society consensus conference recommendation on heart failure 2006: diagnosis
and management. Can J Cardiol. 2006;22(1):23-45.
45. McNamara DM, Holubkov R, Starling, RC, et al. Controlled
trial of intravenous immune globulins in recent-onset
dilated cardiomyopathy. Circulation. 2001;103:2254-2259.
46. Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G.
Peripartum cardiomyopathya new treatment option by
inhibition of prolactin secretion. Am J Obstet Gynecol.
2008;199(4):e5-e6.
47. de Jong JS, Rietveld K, van Lochem LT, Bouma BJ. Rapid left
ventricular recovery after cabergoline treatment in a patient
with peripartum cardiomyopathy. Eur J Heart Fail. 2009;1(2):
220-222.
48. Keogh A, Macdonald P, Spratt P, Marshman D, Larbalestier R,
Kaan A. Outcome in peripartum cardiomyopathy after heart
transplantation. J Heart Lung Transplant. 1994;13(2):202-207.
49. Smith IJ, Gillham MJ. Fulminant peripartum cardiomyopathy
rescue with extracorporeal membranous oxygenation. Int
J Obstet Anesth. 2009;18(2):186-188.
50. Palanzo DA, Baer LD, El-Banayosy A, et al. Successful treatment of peripartum cardiomyopathy with extracorporeal
membrane oxygenation. Perfusion. 2009;24(2):75-79.
51. Gavaert S, van Belleghem Y, Bouchez S, et al. Acute and
critically ill peripartum cardiomyopathy and bridge to
therapeutic options: a single center experience with intraaortic balloon pump, extra-corporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit
Care. 2011;15(2):R93.
52. Rasmusson K, de Jong M, Doering L. Update on heart failure
management. current understanding of peripartum cardiomyopathy. Prog Cardiovasc Nurs. 2007;22(4):214-216.
53. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum
cardiomyopathy. Obstet Gynecol. 2005;105(6):1303-1308.
AJCC AMERICAN JOURNAL OF CRITICAL CARE, March 2012, Volume 21, No. 2
Downloaded from ajcc.aacnjournals.org by guest on July 13, 2014
www.ajcconline.org
Letters
Letters are welcome and encouraged. They should raise points of current interest in the care of critical or high acuity patients or address
topics that previously have appeared in the American Journal of Critical Care. Please be concise; letters are subject to editing for length and
clarity. Include your name, credentials, title (optional), institutional affiliation, city and state, and phone number (for verification, not
publication). Address letters to ajcc@aacn.org. Correspondence also may be sent via eLetters from the journals Web site, www.ajcconline.org.
www.ajcconline.org
AJCC AMERICAN JOURNAL OF CRITICAL CARE, May 2012, Volume 21, No. 3
151
152
doi: http://dx.doi.org/10.4037/ajcc2012826
Response:
On behalf of my coauthors I would like to thank
Dr Reade for his comments and questions. He asks
if nurses were able to make subjective delirium
assessments on patients who had RASS scores of -4
and -5 and were thus rated as unable to assess by
the CAM-ICU raters. The answer is that it was left to
the nurses discretion not to rate patients if they
were comatose. No patients who had RASS scores
of -4 or -5 were subjectively rated by the nurses.
Reade points out a sentence in our abstract
regarding the use of objective criteria with the
CAM-ICU allowing detection of delirium in more
patients,1(pe12) that we could have more clearly
stated as follows: While the overall delirium incidence found with the CAM-ICU was lower than
subjectively rated, objective criteria helped detect
delirium in a significant number of patients who
were subjectively rated non-delirious.
He states that we implied, that the CAM-ICU
is the only correct method for identifying delirium.
This was not our intention. In fact, we emphasized
that the CAM-ICU is not a gold standard for diagnosis of delirium.1(pe18) The truth is that most of the
world uses a subjective and variable method by
which to pay attention to delirium, and thus subjectivity is part of usual care in many ICUs. Our
methodology, chosen a priori and based on previous literature showing that subjectivity misses
hypoactive delirium,2 was to consider a formal and
validated mechanism as the formal and definitive
approach to study discrepancy between the two. At
the same time, however, we clearly stated the fact
AJCC AMERICAN JOURNAL OF CRITICAL CARE, May 2012, Volume 21, No. 3
www.ajcconline.org
Response:
Despite the lack of strong evidence demonstrating that screening for delirium at the bedside using
a validated instrument improves patient outcome,
recent European and North American consensus
guidelines advocate that patients admitted to the
ICU be routinely screened for delirium using either
the ICDSC or the CAM-ICU.1,2 Realizing that bedside delirium screening is not a replacement for a
formal diagnostic evaluation by either a psychiatrist
or neurologist, it nevertheless remains an efficient,
low-risk assessment that will help ICU clinicians
address reversible causes for delirium (when delirium is suspected), avoid treatments for agitation
known to worsen delirium (eg, benzodiazepines),
and promote regular interdisciplinary discussion
regarding the cognitive status of all patients.
Despite questions that remain surrounding the
psychometric properties of the ICSDC and the CAMICU and how one instrument compares to the other,
it is well established that if adequate education is
not provided to ICU clinicians when either of these
instruments are implemented into practice, the performance of each will be less than what has been
observed in formal psychometric evaluations.3-5
Our study was not designed to answer the important questions surrounding the identification of
delirium in the ICU that Reade raises. Instead,
knowing that the ICDSC identifies delirium nearly
as well as a psychiatrist using DSM-IV criteria, we
sought to measure the impact of using the ICDSC,
with or without a multifaceted educational strategy,
on the level of knowledge of ICU nurses regarding
delirium and its assessment and the ability of nurses
to use the ICDSC correctly.6
We did not aim to determine whether use of
the ICDSC identifies delirium correctly. Whereas
the rate of delirium detected in our study was
reported, this was not a focus and we caution readers not to make conclusions surrounding it. Many
of the questions Reade and others have raised surrounding the benefit and accuracy of using currently available delirium screening instruments
require further investigation.7,8
Until this research is completed, we feel our
study provides ICU clinicians with valuable insight
regarding how nurses evaluate delirium when education and a validated instrument are not used, the
intensity of any pedagogical strategy that should
be employed to support ICU delirium screening
efforts, and the members of the ICU team who are
best suited to deliver education in this area.
GAIL GESIN, PHARMD; JOHN W. DEVLIN, PHARMD
Charlotte, North Carolina; Boston, Massachusetts
FINANCIAL DISCLOSURES
None Reported
FINANCIAL DISCLOSURES
None Reported
REFERENCE
1. Guenther U, Weykam J, Andorfer U, Theuerkauf N, Popp J,
Ely EW, Putensen C. Implications of Objective vs Subjective Delirium Assessment in Surgical Intensive Care
Patients. Am J Crit Care. 2012;21:e12-e20.
2. Spronk PE, Riekerk B, Hofhuis J, Rommes JH: Occurrence
of delirium is severely underestimated in the ICU during
daily care. Intensive Care Med. 2009;35:1276-80
doi: http://dx.doi.org/10.4037/ajcc2012456
154
AJCC AMERICAN JOURNAL OF CRITICAL CARE, May 2012, Volume 21, No. 3
www.ajcconline.org
Correction
In the March 2012 article by Johnson-Coyle and
colleagues, Peripartum Cardiomyopathy: Review and
Practice Guidelines (Am J Crit Care. 2012;21[2]:89-98),
Table 1, p. 95, line10 should have read, Extendedrelease metroprolol (starting dose 12.5 mg/daily,
titrated up to 200 mg daily). We regret the error.
doi: http://dx.doi.org/10.4037/ajcc2012737
www.ajcconline.org
AJCC AMERICAN JOURNAL OF CRITICAL CARE, May 2012, Volume 21, No. 3
155